View Clinical Trial (Medical Research Study)

Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy - NCT00858364-(Clinical Trial 276784)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Green Bay
State:  
WI
Zip Code:
Conditions: Non-small Cell Lung Cancer - Anemia - Cancer - Lung Cancer
Purpose: This is a double-blind, randomized, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of metastatic (stage IV) or advanced stage IIIB with malignant pleural effusion NSCLC. Approximately 3000 subjects with metastatic (stage IV) or advanced stage IIIB with malignant pleural effusion NSCLC receiving or about to receive first line chemotherapy will be enrolled into the study. Subjects will be randomized in a 2:1 allocation (Group A: darbepoetin alfa 500 µg Q3W, Group B: placebo Q3W)
Study summary:
Criteria: Inclusion Criteria: - Subjects with metastatic (stage IV) or advanced stage IIIB with malignant pleural effusion NSCLC - Receiving or about to receive first line cyclic chemotherapy for NSCLC and expected to receive at least 2 additional cycles of cyclic chemotherapy - Eastern Cooperative Oncology Group performance status of 0 or 1 as assessed at screening - 18 years of age or older at screening - Life expectancy > 6 months based on the judgment of the investigator and documented at screening - Subjects with chemotherapy-induced anemia as defined as having a hemoglobin level less than or equal to 11.0 g/dL at screening Exclusion Criteria: - Known primary benign or malignant hematologic disorder which can cause anemia - History of, or current active cancer other than NSCLC, with the exception of curatively resected non-melanomatous skin cancer, curatively treated cervical carcinoma in situ, or other primary solid tumors curatively treated with no known active disease present and no curative treatment administered for the last 3 years - Subjects with a history of brain metastasis - Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 100 mmHg), or as determined by the investigator at screening - History of neutralizing antibody activity to rHuEPO or darbepoetin alfa - Uncontrolled angina, uncontrolled heart failure, or uncontrolled cardiac arrhythmia as determined by the investigator at screening. Subjects with known myocardial infarction within 6 months prior to screening - Subjects with a history of seizure disorder taking anti-seizure medication within 30 days of screening - Clinically significant systemic infection or uncontrolled chronic inflammatory disease (eg, rheumatoid arthritis, inflammatory bowel disease) at the time of screening as determined by the investigator - Known seropositivity for HIV or diagnosis of AIDS, positive for hepatitis B surface antigen, or seropositive for hepatitis C virus - History of pure red cell aplasia - History of deep venous thrombosis or embolic event (eg, pulmonary embolism) within 6 months prior to screening - Received any RBC transfusion within 28 days prior to randomization. - Plan to receive any RBC transfusion between randomization and study day 1 - Known previous treatment failure to ESAs (ie, rHuEPO, darbepoetin alfa) - ESA therapy within the 28 days prior to screening - Known hypersensitivity to recombinant ESAs or the excipients contained within the investigational product
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: December 15, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.